
Onyx Biotec Limited - IPO
SMEOnyx Biotec Stock Price

Onyx Biotec IPO Details
Onyx Biotec IPO Subscription
Onyx Biotec IPO Application Wise Breakup
Onyx Biotec IPO Dates
- 13 Nov 2024Opening dateOPD
- 18 Nov 2024Closing dateCOD
- 19 Nov 2024Basis of AllotmentBOA
- 21 Nov 2024Initiation of RefundsIOR
- 21 Nov 2024Credit of SharesCOS
- 22 Nov 2024Listing dateLID
Onyx Biotec IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retain Minimum | 1 | 2000 | ₹122,000 |
Retain Maximum | 1 | 2000 | ₹122,000 |
HNI Minimum | 2 | 4000 | ₹244,000 |
Onyx Biotec IPO Reservation
Promoter Holding
Onyx Biotec IPO Valuations
Onyx Biotec Limited Financial Information
Onyx Biotec Limited's revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.
Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
Assets | 7,476.57 | 7,413.58 | 5,872.36 | 3,683.84 |
Revenue | 1,054.11 | 5,387.43 | 3,961.65 | 4,498.09 |
Profit After Tax | 130.77 | 303.16 | 184.46 | 335.29 |
Net Worth | 2,618.64 | 2,487.87 | 1,820.16 | 1,637.59 |
Reserves and Surplus | 1,286.42 | 1,155.65 | 1,230.00 | 1,047.43 |
Total Borrowing | 3,156.14 | 3,078.04 | 2,922.83 | 1,224.39 |
Amount in ₹ Lakhs |
About Onyx Biotec IPO
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
Strength Of Onyx Biotec IPO
1. One of the prominent contract manufacturers in sterile manufacturing.
2. Quality Assurance and Quality Control of our products.
3. Strong, cordial & long-term relationship with our Marque Clientele.
4. Cost effective production and timely fulfilment of orders.
5. Well experienced management team with proven project management and implementation skills.
Risk Of Onyx Biotec IPO
1. Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
2. Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
3. Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
4. Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.
5. The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.
6. Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.
7. The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
8. The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.
9. Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.
10. Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.
Objectives Onyx Biotec IPO
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
- Prepayment or repayment of all or a portion of certain loans availed by the Company; and
- General Corporate Purposes.
Company Contact Details
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
Registrar Contact Details
Lead Mangers
Horizon Management Private Limited
Market Maker
Giriraj Stock Broking